NCT05438329 - First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Biotech Hunter

Enrollment

1,123

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

DB-1305/BNT325

Administered Injection of Vein (I.V.)

COMBINATION_PRODUCT

Pembrolizumab

Administered I.V.

DRUG

BNT327

Administered I.V.

Trial Locations (30)

10065

RECRUITING

Site 102, New York

22031

RECRUITING

Site 107, Fairfax

33063

RECRUITING

D&H Cancer Research Center Llc, Margate

33321

RECRUITING

BRCR Medical Center Inc., Tamarac

33322

RECRUITING

Site 109, Plantation

37203

RECRUITING

Site 105, Nashville

44718

RECRUITING

Site 101, Canton

48201

RECRUITING

Site 106, Detroit

76017

RECRUITING

Site 110, Arlington

77030

RECRUITING

Site 104, Houston

90095

RECRUITING

Site 108, Los Angeles

90703

RECRUITING

Site 103, Cerritos

110042

RECRUITING

Site 210, Shenyang

130012

RECRUITING

Site 201, Changchun

201315

RECRUITING

Site 207, Shanghai

230031

RECRUITING

Site 217, Hefei

233099

RECRUITING

Site 211, Bengbu

250117

RECRUITING

Site 216, Jinan

276304

RECRUITING

Site 212, Linyi

300060

RECRUITING

Site 203, Tianjin

317004

RECRUITING

Site 220, Taizhou

341006

RECRUITING

Site 208, Ganzhou

350001

NOT_YET_RECRUITING

Site 213, Fuzhou

430021

NOT_YET_RECRUITING

Site 205, Wuhan

450000

RECRUITING

Site 202, Zhengzhou

531200

RECRUITING

Site 209, Nanning

537100

RECRUITING

Site 221, Guigang

611135

NOT_YET_RECRUITING

Site 206, Chengdu

Unknown

RECRUITING

Site 219, Guangzhou

00682

RECRUITING

BRCR GLOBAL Puerto Rico LLC., Mayagüez